<DOC>
	<DOCNO>NCT00996346</DOCNO>
	<brief_summary>Refractory soft tissue sarcoma remain difficult malignancy treat . The mammalian target rapamycin ( mTOR ) enzyme play important role cancer cell survival . mTOR inhibitor , like temsirolimus , show activity sarcoma . Irinotecan chemotherapy drug also use treat sarcoma . However , unknown whether combine two drug would result improved efficacy acceptable toxicity . Therefore , goal phase I study determine maximum tolerate dose ( MTD ) toxicity profile combination temsirolimus irinotecan administer intravenously weekly basis refractory soft tissue sarcoma patient .</brief_summary>
	<brief_title>Phase I/II Study Irinotecan Temsirolimus Patients With Refractory Sarcomas</brief_title>
	<detailed_description>Mammalian target rapamycin ( mTOR ) inhibitor anti-neoplastic agent wide potential range clinical application . The topoisomerase I inhibitor irinotecan potent DNA damaging drug . mTOR appear enhance cancer cell survival follow DNA damage , 's reasonable expect mTOR inhibition combine irinotecan may result synergistic activity . This single arm , non-randomized phase I trial temsirolimus ( mTOR inhibitor ) irinotecan ( topoisomerase I inhibitor ) refractory soft tissue sarcoma patient . Successive group three patient enter escalate dose level . Irinotecan temsirolimus administer weekly three week follow one week rest . One course therefore four week . No intra-patient dose escalation allow . Each patient treat disease progression intolerable side effect develop . Dose limit toxicity assess maximum tolerate dose report . Note trial originally design phase I/II study , phase I portion complete report .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Complement Factor H</mesh_term>
	<criteria>All patient , 10 year age old biopsy proven advance soft tissue sarcoma , fail least one prior treatment metastatic disease eligible measurable evaluable disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) . Patients must life expectancy least 12 week . Prior surgery radiotherapy primary tumor acceptable must complete least 4 week study entry , patient completely recover procedure . Patients must Zubrod performance status 02 . Patients ( legal guardian ) must sign informed consent . Patients adequate bone marrow function define absolute peripheral granulocyte count ≥ 1500 cells/mm3 , hemoglobin &gt; 8 g/dl , platelet count ≥ 100 000/mm3 absence regular red blood cell transfusion requirement . Patients normal hepatic function total bilirubin &lt; upper limit normal Serum glutamic oxaloacetic transaminase ( SGOT ) Serum glutamic pyruvic transaminase ( SGPT ) &lt; 2 time upper limit normal , adequate renal function define serum creatinine ≤ 1.5 upper limit normal . Fasting total cholesterol level &lt; 350 mg/dL triglyceride level &lt; 400 mg/dL require . Women childbearing potential must negative pregnancy test . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month . Patients brain metastasis eligible appropriately treat , asymptomatic long require corticosteroid . Pregnant woman nurse mother eligible . Patients must receive concurrent chemotherapy radiation trial . Patients severe medical illness uncontrolled diabetes , active infection , uncontrolled psychiatric illness eligible . Patients know hypersensitivity temsirolimus sirolimus , receive concomitant antitumor therapy , anticonvulsant therapy , cardiac antiarrhythmic drug eligible .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>INST 0909</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>refractory sarcoma</keyword>
	<keyword>3066K1</keyword>
	<keyword>3066K1-1208</keyword>
	<keyword>20091334</keyword>
</DOC>